Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $85.71, but opened at $79.99. Tempus AI shares last traded at $74.08, with a volume of 7,986,420 shares trading hands.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. William Blair cut Tempus AI from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Stifel Nicolaus lowered Tempus AI from a "buy" rating to a "hold" rating and lifted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler restated a "neutral" rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Guggenheim began coverage on Tempus AI in a research report on Monday, December 9th. They set a "buy" rating and a $74.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $58.55.
Get Our Latest Stock Report on Tempus AI
Tempus AI Stock Performance
The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business has a fifty day simple moving average of $49.75 and a two-hundred day simple moving average of $51.44.
Insider Activity
In other news, CAO Ryan M. Bartolucci sold 13,770 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the sale, the chief accounting officer now directly owns 57,237 shares in the company, valued at $3,434,220. This represents a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,583,467 shares of company stock valued at $130,542,311 in the last quarter.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its stake in Tempus AI by 141,400.0% during the 3rd quarter. International Assets Investment Management LLC now owns 70,750 shares of the company's stock worth $4,004,000 after acquiring an additional 70,700 shares during the period. Dakota Wealth Management bought a new stake in shares of Tempus AI during the 3rd quarter valued at $1,185,000. Janney Capital Management LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at $385,000. Vestor Capital LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at $153,000. Finally, ARK Investment Management LLC boosted its holdings in Tempus AI by 355.0% in the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company's stock worth $134,604,000 after buying an additional 1,855,459 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
